Preferred Label : EGFR Mutant-selective Inhibitor TQB3804;
NCIt synonyms : Epidermal Growth Factor Receptor Inhibitor TQB3804;
NCIt definition : A fourth-generation, orally bioavailable, mutant-selective, epidermal growth factor
receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration,
EGFR mutant-selective inhibitor TQB3804 binds to and inhibits the activity of mutant
forms of EGFR, including the C797S EGFR mutant, thereby preventing EGFR-mediated signaling.
This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor
cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a
key role in tumor cell proliferation and tumor vascularization. TQB3804 inhibits mutated
forms of EGFR including C797S, which prevents covalent bond formation with third-generation
EGFR inhibitor osimertinib leading to drug resistance. TQB3804 may have enhanced anti-tumor
effects in tumors with C797S-mediated resistance when compared to other EGFR tyrosine
kinase inhibitors.;
Molecule name : TQB-3804; TQB 3804;
NCI Metathesaurus CUI : CL1407432;
Origin ID : C173415;
UMLS CUI : C5417974;
Semantic type(s)
- concept_is_in_subset
